Name: Broadening access to biologic medicines that save
Uploaded: 2022-02-07T15:55:00Z
Description: From insulin to vaccines and cancer therapies, biologic medicines have a huge impact on healthcare, and it’s Alvotech’s mission to make such medicines more

Alvotech is a global biopharmaceutical company headquartered in Reykjavik, Iceland. Founded in 2013, the company is dedicated to developing, manufacturing, and delivering high-quality biosimilar medicines. With a strong commitment to accessibility, Alvotech strives to improve patient outcomes worldwide by providing affordable biologic treatments.

The company operates within a robust pharmaceutical landscape, offering a range of biotechnology solutions. Alvotech focuses on the development and commercialisation of biosimilar products that meet rigorous standards of quality and efficacy. Through strategic partnerships and a global presence, Alvotech ensures that its biosimilar portfolio reaches diverse markets, enhancing healthcare access for patients across the globe.

With a team of 1026 employees, Alvotech leverages its expertise in biopharmaceutical manufacturing to deliver excellence in product development and delivery. Under the leadership of CEO Robert Wessman, the company continues to expand its impact in the healthcare sector. Alvotech&#39;s innovative approach and commitment to high standards make it a leader in the field of biosimilar medicines.

Alvotech

Head of Global Supply Chain

Gerhard Helmerich